Evidence map›Paper›PMID 35342877›Full record

ArticleJournal of translational genetics and genomics2021

Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.

M R Chambers, J B Foote, R T Bentley, D Botta, D K Crossman, D L Della Manna, D Estevez-Ordonez, J W Koehler, C P Langford, M A Miller and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational genetics and genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Intracranial Virotherapy for a Canine Hemangioma.International journal of molecular sciences · 2022
    Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

M R ChambersDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
J B FooteDepartment of Microbiology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
R T BentleyDepartment of Neurosurgery, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA.
D BottaDepartment of Microbiology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
D K CrossmanDepartment of Genetics, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
D L Della MannaDepartment of Radiation Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
D Estevez-OrdonezDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
J W KoehlerDepartment of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
C P LangfordDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
M A MillerDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA.
J M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
A K OlivierDepartment of Pathology, College of Veterinary Medicine, Mississippi State University, Starkville, MS 39762, USA.
N B OmarDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
S R PlattDepartment of Neurosurgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
D R RissiAthens Veterinary Diagnostic Laboratory, Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
A ShoresDepartment of Neurology & Neurosurgery, College of Veterinary Medicine, Mississippi State University, Starkville, MS 39762, USA.
D C SorjonenDepartment of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
E S YangDepartment of Radiation Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
A B YankeDepartment of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
G Y GillespieDepartment of Neurosurgery, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USAuburn University · USPurdue University West Lafayette · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6M
Coordinating Center for Canine Immunotherapy Trials and Correlative StudiesU24CA224122 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LONG, QI, MASON, NICOLA J · 2017 to 2021
$3.6M
Canine Immuno NeurotherapeuticsU01CA224151 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CHAMBERS, M R · 2017 to 2021
$2.6M
UAB Research Education Program for Residents and Fellows in NeuroscienceR25NS079188 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STANDAERT, DAVID G. · 2012 to 2022
$1.1M
NCI NIH HHS P30 CA013148NCI NIH HHS U01 CA224151NCI NIH HHS U24 CA224122NCRR NIH HHS M01 RR000032NINDS NIH HHS R25 NS079188
6 · The paper itself

Abstract

Aim: To molecularly characterize the tumor microenvironment and evaluate immunologic parameters in canine glioma patients before and after treatment with oncolytic human IL-12-expressing herpes simplex virus (M032) and in treatment naïve canine gliomas. Methods: We assessed pet dogs with sporadically occurring gliomas enrolled in Stage 1 of a veterinary clinical trial that was designed to establish the safety of intratumoral oncoviral therapy with M032, a genetically modified oncolytic herpes simplex virus. Specimens from dogs in the trial and dogs not enrolled in the trial were evaluated with immunohistochemistry, NanoString, Luminex cytokine profiling, and multi-parameter flow cytometry. Results: Treatment-naive canine glioma microenvironment had enrichment of Iba1 positive macrophages and minimal numbers of T and B cells, consistent with previous studies identifying these tumors as immunologically "cold". NanoString mRNA profiling revealed enrichment for tumor intrinsic pathways consistent with suppression of tumor-specific immunity and support of tumor progression. Oncolytic viral treatment induced an intratumoral mRNA transcription signature of tumor-specific immune responses in 83% (5/6) of canine glioma patients. Changes included mRNA signatures corresponding with interferon signaling, lymphoid and myeloid cell activation, recruitment, and T and B cell immunity. Multiplexed protein analysis identified a subset of oligodendroglioma subjects with increased concentrations of IL-2, IL-7, IL-6, IL-10, IL-15, TNFα, GM-CSF between 14 and 28 days after treatment, with evidence of CD4 Conclusion: These findings indicate that M032 modulates the tumor-immune microenvironment in the canine glioma model.

Indexed as

canine gliomalarge animal modelM032NanoStringOncolytic herpes virustumor microenvironment

Identifiers

PMID35342877
PMCPMC8955901
OpenAlexW4205761303

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.